All In MedTech

Device Trial Radar · NCT05593211

Assess Safety and Performance of the Kronos Electrocautery Device for Electrocautery Procedures Following Coaxial Biopsy Procedures

Feasibility Study of the Kronos Electrocautery Device

Last checked: Nov 20, 2026Latest source record: Jun 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

31

Actual

Start

Oct 17, 2022

Primary completion

Feb 9, 2023

Study completion Feb 9, 2023

Sponsor

Lead sponsor
Single Pass IncNot on our public-company list
Sponsor type
Industry
First posted
Oct 25, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Supportive care
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective for this study is to assess safety and performance of the Kronos Electrocautery Device for electrocautery procedures following coaxial biopsy procedures on areas that include, but are not limited to, liver, kidney, lungs, breasts, soft tissue, etc.

Conditions

  • Hepatic Disease
  • Renal Disease

Interventions

  • Kronos Electrocautery DeviceDevice

    The Kronos Electrocautery Device is a disposable electrocautery device that can cauterize deep tissue through a standard biopsy procedure guide needle. This device is intended to coagulate the tissue surrounding the core biopsy channel during withdrawal to reduce or eliminate significant post-procedural bleeding. Currently, the Kronos Electrocautery Device consists of one (1) size. As such, the existing Kronos Electrocautery Device is chosen as the worst-case condition

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absence of Hematoma FormationTime frame: 14 days
  2. Measure and Categorize Amount of Blood Loss From Biopsy Access SiteTime frame: 1 hour post procedure
  3. Absence of the Need for Ultrasound Examination Due to Observation of BleedingTime frame: 8 hours post procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Long Beach Memorial Medical Center

    Long Beach, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.